Reasons for cessation of mepolizumab, and final pre-cessation level of asthma symptom control
| Reason for cessation of mepolizumab | Number ceased by reason n | Final ACQ-5 score, pre-cessation median (IQR); (number of patients for whom final ACQ-5 data were available) |
| Total patients | 309 | |
| Patient deceased | 2 | 1.40; (n=1) |
| Adverse drug reaction | 6 | 1.8 (1.2–3.0); (n=3) |
| Failed ACQ response | 19 | 3.6 (2.8–4.2); (n=18) |
| Failed to reduce maintenance OCS | 2 | 2.80; (n=1) |
| Patient decision | 4 | 2.1 (1.5,2.9); (n=4) |
| Clinician decision | 11 | 2.3 (2.0–2.6); (n=6) |
| Other | 3 | 2.00; (n=1) |
| Total (not including deceased patients) | 45 | 2.8 (2.0–3.6); (n=34) |
| Total (including deceased patients) | 47 | 2.7 (2.0–3.6); (n=34) |
Data presented as median (IQR), unless otherwise stated. ACQ: Asthma Control Questionnaire; OCS: oral corticosteroids.